Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Thonzonium is a monocationic surface-active agent (cationic surfactant) primarily used as an additive in otic (ear) and nasal pharmaceutical formulations. Its main function is to disperse exudate and cellular debris, thereby enhancing the penetration and tissue contact of co-administered active ingredients such as antibiotics or corticosteroids[2][6][7]. Thonzonium bromide is a component of FDA-approved products like Cortisporin TC and Coly-Mycin S Otic, which are indicated for the treatment of superficial bacterial infections of the external auditory canal and infections following ear surgery[3][4][5]. Mechanistically, thonzonium acts by uncoupling vacuolar ATPase in pathogenic fungi, inhibiting RANKL-induced osteoclast formation (anti-resorptive effect), and has been shown to inhibit SARS-CoV-2 3CL protease with potential broad-spectrum antiviral activity[2][5][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on thonzonium.